1-4 of 4
Mattia Rediti
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial

Mattia Rediti, Danai Fimereli, Magdalena Mileva, Zéna Wimana, David Venet, Patrick Flamen, Thomas Guiot, Elisabeth G.E. de Vries, Carolien P. Schröder, Catharina Willemien Menke-van der Houven van Oordt, Marion Maetens, Samira Majjaj, Denis Larsimont, Françoise Rothé, Christos Sotiriou, Géraldine Gebhart
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 110–121.
https://doi.org/10.1158/1078-0432.CCR-24-1007
Published: 06 January 2025
View article titled, Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Open the PDF for Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00

Andrea Joaquin Garcia, Mattia Rediti, David Venet, Samira Majjaj, Roswitha Kammler, Elisabetta Munzone, Lorenzo Gianni, Beat Thürlimann, István Laáng, Marco Colleoni, Sherene Loi, Giuseppe Viale, Meredith M. Regan, Laurence Buisseret, Françoise Rothé, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4908–4919.
https://doi.org/10.1158/1078-0432.CCR-23-1267
Published: 01 December 2023
View article titled, Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Open the PDF for Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00 in another window
Includes: Supplementary data
Journal Articles

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial

David Venet, Mattia Rediti, Marion Maetens, Debora Fumagalli, David N. Brown, Samira Majjaj, Roberto Salgado, Lajos Pusztai, Nadia Harbeck, Sarra El-Abed, Yingbo Wang, Cristina Saura, Henry Gomez, Vladimir Fedorovich Semiglazov, Evandro de Azambuja, Jens Huober, Paolo Nuciforo, Serena Di Cosimo, Martine Piccart, Sherene Loi, Françoise Rothé, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5607–5618.
https://doi.org/10.1158/1078-0432.CCR-21-1317
Published: 15 October 2021
View article titled, Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
Open the PDF for Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Characterizing CDK12-Mutated Prostate Cancers

Pasquale Rescigno, Bora Gurel, Rita Pereira, Mateus Crespo, Jan Rekowski, Mattia Rediti, Maialen Barrero, Joaquin Mateo, Diletta Bianchini, Carlo Messina, Maria D. Fenor de la Maza, Khobe Chandran, Juliet Carmichael, Christina Guo, Alec Paschalis, Adam Sharp, George Seed, Ines Figueiredo, Maryou Lambros, Susana Miranda, Ana Ferreira, Claudia Bertan, Ruth Riisnaes, Nuria Porta, Wei Yuan, Suzanne Carreira, Johann S. de Bono
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (2): 566–574.
https://doi.org/10.1158/1078-0432.CCR-20-2371
Published: 19 January 2021
View article titled, Characterizing CDK12-Mutated Prostate Cancers
Open the PDF for Characterizing CDK12-Mutated Prostate Cancers in another window
Includes: Supplementary data